Apriori Bio is learning about viruses present today to prepare for outbreaks in the future. The most threatening viruses can evolve faster than new medicines can be developed. To solve this, Apriori built their technology platform, Octavia, which gets ahead of viral evolution by identifying the variants that present the greatest threats. Octavia generates maps of existing and potential variants based on their ability to bind human cells and evade antibody recognition. With this information, Apriori can identify the combination of antibodies that can best protect against current and future viruses. The tools involved in the platform include protein display systems, deep mutational scanning, single-cell sorting and deep sequencing.

<p>Harmful viruses continue to evolve, and Apriori Bio’s goal is to provide humanity with variant-proof protection against these viruses. To achieve that goal, Apriori is building a platform, called Octavia, to design vaccines and antibody drugs that combat existing and potential viral variants. The Octavia platform applies protein display, mutational scanning, single-cell sorting, and deep sequencing to create maps of potential viral variants based on their ability to bind human cells and evade antibodies. Apriori analyzes these maps to identify protective antibody combinations and inform development of new vaccines and antibody drugs. Apriori envisions a future where our vaccines and antibody drugs protect us from not only an existing virus but its future variants that are likely to emerge.</p>


Apriori Bio

Founded: 2020
Location: Cambridge, MA
Employee range: 11 - 50
Funding: $50M A Jul 2022
Investors: Flagship

Short description:

Drug notes:

Long description:

Jobs: